UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

British journal of dermatology (1951), 2014-12, Vol.171 (6), p.1434-1442

2014

Volltextzugriff (PDF)

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

British journal of dermatology (1951), 2014-03, Vol.170 (3), p.705-715

2014

Volltextzugriff (PDF)

An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life

International journal of women's dermatology, 2018-12, Vol.4 (4), p.198-202

2018

Volltextzugriff (PDF)

Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy

International journal of women's dermatology, 2016-12, Vol.2 (4), p.151-153

2016

Volltextzugriff (PDF)

M204 CLINICAL PRESENTATION AND DIAGNOSIS OF HIDRADENITIS SUPPURATIVA

International journal of gynecology and obstetrics, 2012-10, Vol.119 (S3), p.S598-S598

2012

Volltextzugriff (PDF)

490 Feasibility of examining fluorescence of follicular sebum and C. acnes after pool water immersion

Journal of investigative dermatology, 2020-07, Vol.140 (7), p.S66-S66

2020

Volltextzugriff (PDF)

1134 Comparison of placebo response rates in failed vs successful phase 2/3 clinical trials in hidradenitis suppurativa and atopic dermatitis

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S194-S194

2023

Volltextzugriff (PDF)

423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S73-S73

2023

Volltextzugriff (PDF)

480 Differences in timing of prescriptions after FDA approval in psoriasis based on race

Journal of investigative dermatology, 2023-05, Vol.143 (5), p.S82-S82

2023

Volltextzugriff (PDF)

445 Diagnostic delay in hidradenitis suppurativa not associated with severity

Journal of investigative dermatology, 2020-07, Vol.140 (7), p.S59-S59

2020

Volltextzugriff (PDF)

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

Journal of the European Academy of Dermatology and Venereology, 2014-03, Vol.28 (3), p.333-337

2014

Volltextzugriff (PDF)

685 Evaluation of racial differences in prescription rates of systemic medications for psoriasis and psoriatic arthritis

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S118

2022

Volltextzugriff (PDF)

681 Clinical trials in hidradenitis suppurativa and psoriasis under-represent certain gender, ethnic, and racial groups

Journal of investigative dermatology, 2022-08, Vol.142 (8), p.S117

2022

Volltextzugriff (PDF)

A new era in skin care: the omics revolution: Editorial

British journal of dermatology (1951), 2012-06, Vol.166, p.iii-iv

Kimball, A.B.

2012

Volltextzugriff (PDF)

The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study

British journal of dermatology (1951), 2011-11, Vol.165 (5), p.1066-1073

2011

Volltextzugriff (PDF)

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

Journal of the European Academy of Dermatology and Venereology, 2016-06, Vol.30 (6), p.989-994

2016

Volltextzugriff (PDF)

EE405 Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa

Value in health, 2024-06, Vol.27 (6), p.S131-S131

2024

Volltextzugriff (PDF)

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1039-1049

2019

Volltextzugriff (PDF)

Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, 2021-12, Vol.35 (12), p.2342-2342

2021

Volltextzugriff (PDF)

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

British journal of dermatology (1951), 2017-11, Vol.177 (5), p.1401-1409

2017

Volltextzugriff (PDF)

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

British journal of dermatology (1951), 2014-07, Vol.171 (1), p.137-147

2014

Volltextzugriff (PDF)

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

Journal of the European Academy of Dermatology and Venereology, 2019-01, Vol.33 (1), p.19-31

2019

Volltextzugriff (PDF)

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

British journal of dermatology (1951), 2018-09, Vol.179 (3), p.615-622

2018

Volltextzugriff (PDF)

Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis

British journal of dermatology (1951), 2016-07, Vol.175 (1), p.157-162

2016

Volltextzugriff (PDF)

595 Opinions and practices of primary care physicians managing psoriasis

Journal of investigative dermatology, 2019-05, Vol.139 (5), p.S102-S102

2019

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(90)

Publikationsform

Artikel
(94)

Sprache

Englisch
(91)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

Dermatology
(56)
Life Sciences & Biomedicine
(56)
Science & Technology
(56)
Humans
(47)
Female
(32)
Male
(29)
Adult
(26)
Middle Aged
(26)
Psoriasis
(24)
Psoriasis - Drug Therapy
(18)
Severity Of Illness Index
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Monoclonal Antibodies
(13)
Quality Of Life
(12)
Treatment Outcome
(11)
Clinical Trials
(10)
Dermatologic Agents - Therapeutic Use
(10)
Psoriasis. Parapsoriasis. Lichen
(10)
Psoriasis - Complications
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life

Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy

M204 CLINICAL PRESENTATION AND DIAGNOSIS OF HIDRADENITIS SUPPURATIVA

490 Feasibility of examining fluorescence of follicular sebum and C. acnes after pool water immersion

1134 Comparison of placebo response rates in failed vs successful phase 2/3 clinical trials in hidradenitis suppurativa and atopic dermatitis

423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa

480 Differences in timing of prescriptions after FDA approval in psoriasis based on race

445 Diagnostic delay in hidradenitis suppurativa not associated with severity

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

685 Evaluation of racial differences in prescription rates of systemic medications for psoriasis and psoriatic arthritis

681 Clinical trials in hidradenitis suppurativa and psoriasis under-represent certain gender, ethnic, and racial groups

A new era in skin care: the omics revolution: Editorial

The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

EE405 Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis

595 Opinions and practices of primary care physicians managing psoriasis

Suchergebnisse filtern